Moderna’s Fiscal Q1 2025 Earnings: Analysts Expect Losses to Narrow

With a market capitalization of $9.6 billion, Moderna, Inc. (MRNA) is a leading biotechnology firm based in Cambridge, Massachusetts. The company specializes in creating messenger RNA (mRNA) medicines and vaccines, and it gained prominence for its COVID-19 vaccine, Spikevax. Building on its past success, Moderna is advancing its diverse pipeline, which targets respiratory, latent, and enteric viruses, alongside efforts in cancer and rare diseases. Investors are looking forward to the company’s fiscal Q1 2025 earnings, which are set to be released before market opening on Thursday, May 1.

Anticipated Earnings Report and Historical Performance

Analysts project that Moderna will report a loss of $2.91 per share for the upcoming quarter, which represents a 5.2% improvement compared to a loss of $3.07 per share in the same quarter last year. Notably, the company has outperformed Wall Street’s bottom-line estimates in the past four quarters, with a substantial 7.1% beat over the consensus EPS estimate in Q4 2024.

For the full fiscal year 2025, analysts project MRNA to incur a loss of $10.15 per share, indicating a 14.4% rise from $8.87 per share loss recorded in fiscal 2024.

Moderna’s Stock Performance and Analyst Ratings

Over the past year, MRNA shares have struggled significantly, experiencing a 75.9% decline compared to a 4.1% gain in the S&P 500 Index ($SPX) and a 3.8% dip in the Health Care Select Sector SPDR Fund (XLV)

Despite a substantial year-over-year revenue decline, shares of Moderna rose 3.4% on February 14, primarily due to its Q4 2024 revenue of $966 million, which exceeded analysts’ expectations. Furthermore, investors welcomed the company’s initial $15 million in sales from its newly approved RSV vaccine, mRESVIA. Alongside these developments, Moderna has initiated cost-cutting strategies, driving a 27% reduction in operating expenses—indicative of improved financial control.

Analysts’ Consensus on MRNA Stock

Currently, the consensus rating from analysts regarding Moderna’s stock remains “Hold.” Of the 26 analysts monitoring the stock, evaluations are mixed, with three marking it as “Strong Buy,” 19 as “Hold,” one as “Moderate Sell,” and three as “Strong Sell.” Presently, MRNA trades below the average analyst price target of $59.26.

On the date of publication, Sohini Mondal did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article are for informational purposes only. For further information, please refer to the Barchart Disclosure Policy here.

More news from Barchart

The views and opinions expressed herein are solely those of the author and do not necessarily reflect those of Nasdaq, Inc.